Acadia Pharmaceuticals Welcomes New Chief Commercial Officer
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has made a significant announcement regarding its leadership. The company has appointed Thomas Andrew Garner as the Chief Commercial Officer, effective immediately. In this role, Mr. Garner will oversee Acadia's commercial strategy and operations, focusing on plans that aim for sustained growth and the expansion of its product portfolio across various markets.
Insights from Leadership
Catherine Owen Adams, Acadia’s CEO, shared her enthusiasm about Mr. Garner's appointment, stating that he is an accomplished commercial executive with a proven track record of driving brand success. She emphasized his extensive experience in brand launches, particularly in complex therapeutic areas.
Key Responsibilities and Goals
As Chief Commercial Officer, Mr. Garner will not only lead existing commercial strategies but will also be pivotal in the ongoing launch of DAYBUE™ in the U.S. and preparing for international market introductions. He recognizes the potential growth in Acadia's offerings, including major franchises like NUPLAZID and DAYBUE.
Mr. Garner's Rich Background in Pharmaceuticals
Mr. Garner comes to Acadia with over 25 years of experience in the pharmaceutical industry. His expertise spans across multiple areas including sales, marketing, and business development. Prior to joining Acadia, he was the senior vice president at Lexicon Pharmaceuticals, where he played a crucial role in revamping the relaunch of INPEFA (sotagliflozin) as well as crafting comprehensive commercial strategies for their entire product line.
A Track Record of Success
Before his tenure at Lexicon, Mr. Garner held several key positions at Bristol Myers Squibb (BMS), where he was part of the team that managed over $10 billion in revenue for significant brands. His leadership in global launches of OPDIVO® and YERVOY® showcases his capability to drive successful product entries in challenging markets.
Promotions within the Company
Alongside Mr. Garner's appointment, Acadia Pharmaceuticals announced the promotion of Holly Valdiviez to Senior Vice President of the Neuropsychiatric Franchise. Ms. Valdiviez's leadership in both sales and marketing for NUPLAZID will continue as she reports directly to Mr. Garner, ensuring a cohesive approach to the company’s goals.
Acadia's Commitment to Neuroscience
Acadia Pharmaceuticals has been a pioneering force in neuroscience, focusing on breakthrough solutions that significantly impact patients’ lives. The company made history by developing the first FDA-approved drug that addresses hallucinations and delusions related to Parkinson’s disease psychosis, as well as the first approved treatment for Rett syndrome in the U.S. and Canada.
With ongoing clinical-stage efforts targeted at conditions like Prader-Willi syndrome and Alzheimer’s disease-related psychosis, Acadia is dedicated to expanding its reach and improving therapeutic options for patients suffering from neuropsychiatric disorders.
Frequently Asked Questions
What position has Thomas Garner been appointed to at Acadia?
Thomas Garner has been appointed as the Chief Commercial Officer at Acadia Pharmaceuticals.
What are Mr. Garner’s responsibilities as CCO?
As CCO, Mr. Garner is responsible for leading Acadia's commercial strategy, operations, and overseeing the launch of new products.
What prior experience does Mr. Garner have?
Mr. Garner brings over 25 years of pharmaceutical experience, having held key roles at Lexicon Pharmaceuticals and Bristol Myers Squibb.
What is Acadia's focus in its drug development?
Acadia focuses on developing treatments for neuropsychiatric symptoms, including conditions like Parkinson's disease psychosis and Rett syndrome.
Who will report to Mr. Garner in his new role?
Holly Valdiviez, promoted to Senior Vice President, Neuropsychiatric Franchise, will report directly to Mr. Garner.
